Today: 15 July 2026
Intel (NASDAQ:INTC) Turns a $400 Million High-NA Tool Into a Manufacturing Hedge

Intel (NASDAQ:INTC) Turns a $400 Million High-NA Tool Into a Manufacturing Hedge

SANTA CLARA, California, July 15, 2026, 07:09 PDT

Intel Corporation has begun high-volume production of a subset of Panther Lake laptop chips using ASML Holding N.V. ’s High NA EUV system, making it the first chipmaker to ship a volume logic product with the technology. The more useful signal for investors is what Intel did not do: selected 18A layers are also qualified on ASML’s established NXE platform at matched yields, so Panther Lake is not tied to the new machine.

This matters now because Intel reports second-quarter results next week with its foundry, the contract chipmaking unit, still carrying large losses and capital needs. The production milestone proves readiness on a real product; it does not yet prove lower wafer costs, high tool use or demand from outside chip designers.

High NA EUV, a higher-resolution system that uses light to print chip circuits, is estimated to cost about $400 million, roughly twice a standard EUV scanner. One such tool equals 8.1% of Intel’s $4.963 billion first-quarter gross capital spending and 2.4% of its $17 billion 2026 plan. Those are scale comparisons, not a disclosed Intel purchase price.

Capital yardstickReported figureOne estimated $400 million scanner
High NA EUV scannerAbout $400 millionBase
Intel Q1 gross capital spending$4.963 billion8.1%
Intel 2026 capital-spending plan$17 billion2.4%

Percentages are calculated from reported figures. The scanner price is an industry estimate, not a confirmed Intel purchase price.

The safeguard is dual qualification. ASML said the selected 18A layers can run on High NA in Oregon or on NXE at matched yields, letting Intel keep volume on its installed fleet while it improves High NA setup, uptime and manufacturing control. Panther Lake is carrying the learning cycle, not depending on it.

Intel’s second manufacturing move this week is less experimental. It committed €5 billion ($5.7 billion) to expand Intel 3 capacity in Ireland for Xeon 6 and next-generation server chips, mainly through upgrades and tools inside existing cleanroom space; most of the program is due by the end of 2027. Intel Foundry general manager Naga Chandrasekaran said, “The demand for servers, the demand for AI is driving a significant increase in the need for Intel 3 wafers.” Reuters

MeasureOregon: Intel 18A and High NAIreland: Intel 3
Product disclosedSubset of Panther Lake client chipsXeon 6 and next-generation Xeon
Capital markerAbout $400 million per High NA tool, estimated€5 billion multi-year program
Immediate aimProduction data and future-node flexibilityMore wafer output and factory use
Outside wafer customer namedNone in the announcementNone in the announcement

The capital figures are not directly comparable: one is an estimated machine price, the other a multi-year factory program.

The financial gap remains wide. Intel Foundry posted first-quarter revenue of $5.421 billion and a segment operating loss of $2.437 billion, an implied negative 45.0% margin. Intersegment eliminations, sales between Intel units removed when their accounts are combined, were $5.251 billion, or 96.9% of foundry revenue; Intel says the line also captures inventory accounting, so the ratio is not a direct measure of outside sales. It still shows how heavily factory economics rest on Intel products.

Chandrasekaran said the High NA work “shows how High NA EUV can be integrated into advanced semiconductor manufacturing at scale.” His next point was just as telling: Intel’s existing tools are providing “increased output” while the company develops future options. That sounds less like a fleet switch than a controlled production choice. ASML

ASML’s own quarter offers a favorable demand backdrop. The Dutch supplier reported second-quarter revenue of €9.33 billion, raised its 2026 revenue forecast to €43 billion to €45 billion and said it would expand capacity by 30% in each of the next two years. Degroof Petercam analyst Michael Roeg called the results “blow-out results across the board.” Reuters

But the economics could still turn the other way. If High NA’s precision does not offset its price and integration burden, Intel may gain process knowledge without cutting wafer cost; if Panther Lake or Xeon demand slows, the Irish build could leave more fixed cost underused. Dual qualification lowers production risk, not return-on-capital risk.

Intel shares were down 1.8% at $105.82 in early Wednesday trading, while ASML’s U.S.-listed shares were little changed. Intel reports on July 23, when investors will look for foundry losses, gross capital spending and evidence that 18A is drawing outside volume. The technical first is real. The revenue proof is still due.

Marcin Frąckiewicz is the founder and CEO of TS2 Space, a satellite communications company serving customers around the world. A graduate of the Warsaw School of Economics (SGH), he has more than two decades of experience in telecommunications, satellite services and technology ventures. He writes about satellite communications, space technology, artificial intelligence and the stock market, with a particular focus on technology companies, semiconductors, emerging industries and the trends shaping global innovation. Follow Marcin Frąckiewicz on Google News, Facebook. or Linkedin.

Stock Market Today

  • Nuvalent Moves to Delist Class A Shares from Nasdaq
    July 15, 2026, 10:32 AM EDT. Nuvalent, Inc. (NASDAQ: NUVL) has filed Form 25 to take its Class A common stock off the Nasdaq Stock Market. Nasdaq certified the filing meets SEC rules. The delisting is set to take effect July 15, 2026. Form 25 is the SEC form used to remove a stock under Section 12(b) of securities law. The company is based in Cambridge, Massachusetts.
Zhongji Innolight (SHE:300308) $7 Billion Hong Kong Plan Would Equal 84% of Its Asset Base
Previous Story

Zhongji Innolight (SHE:300308) $7 Billion Hong Kong Plan Would Equal 84% of Its Asset Base

Johnson & Johnson leans on two main drugs for almost all Q2 sales growth
Next Story

Johnson & Johnson leans on two main drugs for almost all Q2 sales growth

Go toTop